US Patent Issued on Feb. 17 for "Identification of inhibitor peptides to bind with n-terminal spike (s) and nonstructural protein (NSP) sequences of SARS-COV2 b.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapy" (South Carolina Inventor)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,840, issued on Feb. 17.

"Identification of inhibitor peptides to bind with n-terminal spike (s) and nonstructural protein (NSP) sequences of SARS-COV2 b.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapy" was invented by Subhajit Dasgupta (Charleston, S.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The identified peptide sequences form moderate to strong heterodimeric complexes with SARS-COV2 (B.1.617.2) virus Spike envelope proteins and a range of virus nonstructural protein sequences NSP1-14. These identified peptides are proposed to use in antiviral immunotherapy and supportive combination with...